Literature DB >> 16569854

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Keso Skhirtladze1, Doris Hutschala, Tatjana Fleck, Florian Thalhammer, Marek Ehrlich, Thomas Vukovich, Markus Müller, Edda M Tschernko.   

Abstract

Soft tissue infections constitute a serious complication following surgery in diabetic patients and frequently require the administration of vancomycin. However, despite antibiotic treatment, mortality of patients with postoperative infections remains high and might be related to an impaired penetration of anti-infective agents to target tissues. Therefore, the present study was designed to measure vancomycin tissue concentrations in six diabetic and six nondiabetic patients after cardiac surgery. Vancomycin was administered as a continuous intravenous infusion at an infusion rate of 80 to 120 mg/h. Vancomycin concentrations in soft tissues and plasma were measured in all patients during steady state as "therapeutic window" concentrations in plasma by microdialysis on day 8+/-4 after initiation of vancomycin treatment. Vancomycin tissue concentrations in diabetic patients were significantly lower than in nondiabetics (3.7 mg/liter versus 11.9 mg/liter; P=0.002). The median vancomycintissue/vancomycinplasma concentration ratio was 0.1 in diabetic patients and 0.3 in nondiabetics (P=0.002). Our study demonstrated that vancomycin penetration into target tissues is substantially impaired in diabetic patients versus nondiabetics. Insufficient tissue concentrations could therefore possibly contribute to failure of antibiotic treatment and the development of antimicrobial resistance in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569854      PMCID: PMC1426928          DOI: 10.1128/AAC.50.4.1372-1375.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance.

Authors:  S Harbarth; M H Samore; D Lichtenberg; Y Carmeli
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

2.  Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus.

Authors:  H M Aucken; M Warner; M Ganner; A P Johnson; J F Richardson; B D Cookson; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

Review 3.  Science, medicine, and the future: Microdialysis.

Authors:  Markus Müller
Journal:  BMJ       Date:  2002-03-09

4.  Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.

Authors:  E Presterl; P Mueller-Uri; A Grisold; A Georgopoulos; W Graninger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-07       Impact factor: 3.267

5.  Surgery and intensive care procedures affect the target site distribution of piperacillin.

Authors:  M Brunner; T Pernerstorfer; B X Mayer; H G Eichler; M Müller
Journal:  Crit Care Med       Date:  2000-06       Impact factor: 7.598

6.  Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.

Authors:  M Wysocki; F Delatour; F Faurisson; A Rauss; Y Pean; B Misset; F Thomas; J F Timsit; T Similowski; H Mentec; L Mier; D Dreyfuss
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Tissue distribution of imipenem in critically ill patients.

Authors:  Irmgard Tegeder; Achim Schmidtko; Lutz Bräutigam; Andreas Kirschbaum; Gerd Geisslinger; Jörn Lötsch
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

8.  Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery.

Authors:  R Kitzes-Cohen; D Farin; G Piva; S Ivry; R Sharony; R Amar; G Uretzky
Journal:  Ther Drug Monit       Date:  2000-12       Impact factor: 3.681

9.  Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.

Authors:  Christian Joukhadar; Nikolas Klein; Bernhard X Mayer; Nicole Kreischitz; Georg Delle-Karth; Peter Palkovits; Gottfried Heinz; Markus Müller
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

Review 10.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.

Authors:  F C Tenover; J W Biddle; M V Lancaster
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  27 in total

1.  In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling.

Authors:  Andrea N Edginton; Gertrud Ahr; Stefan Willmann; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

4.  Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis.

Authors:  Olivier Mangin; Saïk Urien; Jean-Luc Mainardi; Jean-Yves Fagon; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

5.  Measurement of vancomycin hydrochloride concentration in the exudate from wounds receiving negative pressure wound therapy: a pilot study.

Authors:  Yukiko Ida; Hajime Matsumura; Masami Onishi; Sayaka Ono; Ryutaro Imai; Katsueki Watanabe
Journal:  Int Wound J       Date:  2014-03-28       Impact factor: 3.315

6.  In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.

Authors:  Yukihiro Hamada; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

7.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 8.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 9.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 10.  Rationale for one stage exchange of infected hip replacement using uncemented implants and antibiotic impregnated bone graft.

Authors:  Heinz Winkler
Journal:  Int J Med Sci       Date:  2009-09-04       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.